AI-Powered Formulation Intelligence

From Empirical Formulation
to Intelligence-Driven
Biopharmaceutical Formulation

FormulytiX is an AI-powered formulation intelligence platform currently in active development. Initial scientific and MVP work focuses on STABILIS and DEVIX for monoclonal antibodies and recombinant proteins, beginning with high-concentration SC formulations. The wider roadmap spans six specialised modules, supported by NeXus, the Analogous Molecule Engine, and a Validation Module that compares predictions with experimental results. All outputs require expert scientific review and are not intended as validated regulatory submissions.

Explore Modules → How It Works
LEXIS · Excipient Intelligence
mAb Formulation Analysis
mAb SC Aggregation Risk: Low
Illustrative Output · Conceptual · Non-Validated
High
Stability Confidence
ICH Q5C
Guideline Framework
Sources
Source-Linked Evidence
Early
Decision Support
🔬
Source-Linked Scientific Evidence
🇨🇭
Swiss data residency · Azure CH-North
📋
Regulatory Workflow Support
🛡️
Designed for Traceability
🔗
Planned BioXion Interoperability
Market Convergence

Why Now Is the Moment
for Formulation Intelligence

Four converging forces create an unprecedented market window for a focused, regulatory-aware formulation intelligence platform.

01
Evidence Retrieval Maturity
Modern evidence-retrieval and language-model systems can support source-linked scientific review when combined with controlled workflows, transparent rationale, and expert evaluation.
02
Exploding Knowledge Base
Rapid growth of publicly available peer-reviewed literature, patent databases, EPARs, and FDA product review documents creates the infrastructure for scientifically meaningful AI depth.
03
Rising Biologics Complexity
Pipelines shift toward high-concentration SC injectables, bispecifics, and novel modalities — empirical formulation approaches are reaching their practical limits.
04
Late-Stage Development Pressure
Industry-wide pressure is increasing the need to identify stability, developability, and manufacturability risks earlier, before they become costly late-stage development constraints.
Six Specialized Modules

Full-Spectrum
Formulation Intelligence

The six-module roadmap is designed to support connected formulation intelligence across biologics, vaccines, and complex molecules — from early candidate selection through regulatory-readiness workflows.

Module A
LEXIS
Literature & Prior-Art Intelligence
Further expansion
Planned retrieval from selected scientific, regulatory, and patent sources is intended to support source-linked formulation precedent review. Outputs are designed to remain traceable to available sources and subject to expert evaluation; source coverage will depend on availability, licensing, and implementation. Prior-art and patent signals are provided for scientific and formulation awareness only — not freedom-to-operate, patentability, or legal advice.
Formulation precedent retrieval for mAbs & recombinant proteins
Excipient compatibility with confidence-weighted rationale
FDA Purple Book / EMA EPAR regulatory precedent mining
Module B
ROUTEX
Delivery Route & Administration Optimization
Further expansion
Scenario-based modeling of delivery route feasibility. Supports early go/no-go decisions before costly clinical studies — essential for patient-centric SC injectable design.
Viscosity modeling & injectability assessment
Auto-injector and device platform compatibility mapping
High-concentration protein concentration optimization
Module C
STABILIS
Stability Simulation & Risk Modeling
Phase 1
In silico reasoning over degradation pathways and relative stability risk. Operates as a decision-support layer alongside ICH stability studies. Ranks relative risk across candidates and formulations — it does not predict regulatory shelf-life.
ICH Q1A & Q5C study design framework generation
Relative stability risk ranking across candidates & formulations
Accelerated & stress-condition degradation reasoning
Module D
DEVIX
Drug–Excipient & Delivery Intelligence
Phase 1
Developability and formulation-interaction analysis — relative ranking of candidates and formulations by viscosity, aggregation propensity, solubility and self-interaction, together with drug–excipient compatibility, SubQ injection-volume constraints and container-closure risk. Built on the same physicochemical model as STABILIS. Does not replace laboratory compatibility studies.
Relative developability ranking before scarce material is committed
Viscosity, aggregation, solubility & self-interaction assessment
Drug–excipient compatibility, injection volume & container-closure risk
Module E
COMPEX
Comparability Support
Further expansion
Structured comparability reasoning across formulation changes — reformulation, tech transfer, excipient/container change and scale-up. Supports the comparability rationale; does not replace formal comparability studies.
Change scoping & impacted-CQA identification
Reference & prior-formulation evidence mapping
Comparability summary & rationale (expert-reviewed)
Module F
REGIX
Regulatory Mapping & Gap Identification
Further expansion
AI-assisted mapping of formulation outputs to ICH / FDA / EMA / Swissmedic expectations, with gap identification — not regulatory drafting, legal advice, or regulatory advice. Future interoperability with BioXion is planned to connect formulation evidence with relevant development and regulatory-intelligence workflows.
CTD Section 3.2.P expectation mapping & gap report (EMA / FDA / Swissmedic)
Dossier cross-reference consistency checker
ICH / EMA / FDA guideline currency monitoring
Cross-Cutting Capability

The Analogous
Molecule Engine

A planned cross-cutting capability intended to provide shared molecular context across the six specialised modules as they come online, beginning with STABILIS and DEVIX.

The AME is intended to contextualise new candidates using relevant scientific, formulation, and regulatory precedents. Detailed similarity methods, source-selection logic, weighting, and retrieval architecture are proprietary.

⚡ Intended to reduce early-stage formulation intelligence gathering time — evidence-anchored from day one.
LEXIS
REGIX
STABILIS
DEVIX
COMPEX
ROUTEX
AME
Core
Technical Foundation

Designed for Regulatory-Aligned
Scientific Environments

🧠
Evidence-Linked Intelligence
FormulytiX is designed to support source-linked scientific reasoning, transparent rationale, and expert review. Evidence coverage and traceability will depend on the selected sources, their availability, and the implemented workflow.
🔬
NeXus — Controlled AI Layer
NeXus is the planned controlled AI layer supporting FormulytiX. It is intended to combine governed scientific reasoning, source-linked evidence support, privacy-preserving controls, and expert review. Detailed orchestration, model selection, and data-protection methods are proprietary and will be defined through the final technical and IP architecture.
🏗️
Planned Interoperability
API-based interoperability with selected discovery, laboratory, and development systems is planned as part of the phased product roadmap. Future integration is intended to reduce manual re-entry while preserving controlled, expert-reviewed workflows.
🇨🇭
Swiss Data Residency
FormulytiX is designed for deployment on Azure Switzerland North, with data residency in Switzerland. Customer-specific security, privacy, and external AI-processing requirements are intended to be governed through the final architecture and contractual controls.
⚖️
Governed AI Support
FormulytiX is intended to combine structured scientific logic, evidence retrieval, and governed AI support. Outputs are designed to include source links, confidence information where appropriate, and clear expert-review requirements. Detailed orchestration and scoring methods are proprietary.
🔗
Planned BioXion Interoperability
Future interoperability with BioXion is intended to connect formulation evidence and decisions with applicable development, analytical, quality, partner, and regulatory-intelligence workflows.
Target Audience

Built for Three
Critical Segments

01
Biotech & Virtual Pharma
Limited CMC Capacity
Organisations with promising biologics, vaccine, or complex molecule candidates but limited internal CMC formulation expertise. FormulytiX is designed to deliver AI-assisted formulation guidance, intended to support early development stages where formulation decisions carry the highest downstream impact.
02
CDMOs
Multi-Project Pipeline Management
Organisations managing formulation development across multiple client programs — biologics, vaccines, and complex molecules — simultaneously. FormulytiX is designed to support scalable scientific review, throughput, and evidence traceability across complex portfolios.
03
Mid-Size Biopharma
AI-Augmented Internal Teams
Organisations with internal CMC teams seeking to identify stability and developability risks earlier, support regulatory timelines, and systematise formulation decision-making across their full pipeline — biologics, vaccines, and complex molecules.
Planned HTS Interoperability

FormulytiX + BioXion
Complementary Intelligence Platforms

FormulytiX
Formulation Intelligence
⟶
BioXion ↗
Development Intelligence
Formulation Evidence
⟶
Development Context
⟶
Regulatory Context

Planned interoperability is intended to connect formulation evidence and decisions with relevant development and regulatory-intelligence workflows.

🔁
REGIX → BioXion Interoperability
Future interoperability is intended to connect REGIX outputs with BioXion's applicable Program Development and Regulatory Intelligence workflows, helping reduce manual re-entry and cross-document inconsistency while retaining expert oversight.
🔄
Drug Discovery → FormulytiX → BioXion
Planned API interoperability is intended to allow selected discovery platforms to transfer structured candidate information into FormulytiX and, later, connect relevant formulation outputs with BioXion ↗. This remains a roadmap capability rather than a deployed integration.
🏢
Distinct, Complementary Roles
FormulytiX focuses on formulation intelligence, while BioXion ↗ connects broader development, quality, analytical, partner, regulatory, and operational information across biopharma programs. Future interoperability is planned while the two products retain distinct roles and development roadmaps.
Development Roadmap

Phased Deployment
for Maximum Impact

Phase 1
STABILIS & DEVIX Shared Core
  • STABILIS & DEVIX built on one shared physicochemical model
  • Initial scientific validation focused on high-concentration SC formulations, followed by staged extension to IV and IM
  • NeXus — controlled AI layer with governed scientific and language-model support
  • Monoclonal antibodies & recombinant proteins — initial applicability domain
  • Scientific and experimental validation with a Swiss academic research partner
  • Validation Module — wet-lab protocol support and structured comparison of FormulytiX predictions with experimental results
  • Targeted pilot with 2–3 biotech or CDMO partners
Further expansion
Additional Modules,
Modalities & Routes
  • Analogous Molecule Engine (AME) — planned activation across modules as they come online
  • LEXIS — Literature & Prior-Art Intelligence
  • ROUTEX — Delivery Route Optimization
  • COMPEX — Comparability Support
  • REGIX — Regulatory Mapping & Gap Identification
  • BsAbs, ADCs, viral vectors, mRNA/LNP systems
  • Oligonucleotides, peptides, vaccines, selected small molecules (BCS Class II/IV)
  • Routes of administration beyond SC, IV and IM
  • Planned API interoperability with AI Drug Discovery platforms
  • Planned BioXion interoperability & commercial go-to-market

Ready to Transform
Your Formulation Process?

Express interest in becoming a future scientific, data, design, or validation partner for FormulytiX — across biologics, vaccines, and complex molecules.

Express Your Interest → Learn More at HTS

Important Notice: FormulytiX is designed as an AI-powered formulation intelligence platform for biologics, vaccines, and complex molecules — currently in active development. All outputs require expert scientific evaluation and are not intended for direct regulatory submission. Platform capabilities described represent the intended product scope — not a deployed production system.